SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as investors weigh the impact of recent earnings, a partnership with OpenAI, and broader consumer spending trends. The community is discussing whether Target can regain its footing amidst increased competition and shifting consumer preferences, with some citing concerns over store experience and brand perception, while others express optimism about its long-term potential and dividend payouts. News of layoffs and cost-cutting measures are also being considered as potential catalysts for change.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to positive initial results from a Phase 1b trial of its drug, paxalisib, in combination with other therapies for metastatic triple-negative breast cancer. The community is discussing the potential of these early results, particularly a significant reduction in tumor cells, while some traders are wary of the stock's history and potential for dilution. Bullish investors are hoping this positive development will help regain NASDAQ compliance.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is trending due to a recently awarded $44M DARPA contract to advance its Very Low Earth Orbit mission using its SabreSat platform, sparking optimism about the company's growth potential. The community is actively discussing the significance of this contract and its potential impact on Redwire's position in the space industry, with some members predicting substantial future gains. Despite some bearish sentiment and concerns about dilution, the DARPA contract win is seen as a positive catalyst for the stock.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's earnings release is the primary catalyst, with the market anticipating significant movement based on the report's implications for the AI sector. Community discussions revolve around potential partnerships, Saudi Arabian investments, and whether the stock is overvalued or poised for further gains. Some traders express concern about a potential "sell the news" event, while others anticipate a substantial rally if NVIDIA delivers strong results.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is trending due to its strong community and potential within the Injective ecosystem, particularly as Injective's EVM mainnet launch approaches. Community members highlight $NONJA's strong performance against $INJ, its high burned liquidity, and the unique NFT collections. The community sees $NONJA as a leveraged play on $INJ, anticipating significant gains as the Injective ecosystem develops.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid discussions around critical mineral supply chains and potential government support for deep-sea mining. Community members are debating the stock's volatility and future catalysts, particularly regarding regulatory approvals and partnerships. Bullish sentiment is building, with some traders anticipating a significant price increase soon.

SEMrush Holdings, Inc. engages in the provision of an online visibility management software-as-a-service platform. The company was founded by Oleg Shchegolev and Dmitry Melnikov in 2008 and is headquartered in Boston, MA.

SEMrush Holdings Inc - Ordinary Shares - Class A

Fueled by a WSJ report, Semrush is trending as Adobe is reportedly nearing a $1.9 billion acquisition of the software provider. The potential buyout at $12 per share has sparked significant community discussion, particularly regarding the deal's implications for both companies and potential short squeezes.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals' stock is trending due to mixed reactions to recent sickle cell disease study results, specifically hitting endpoints on hemoglobin response but missing goals for pain crisis reduction. The community is debating the impact of these mixed results on the drug's future and management's handling of the situation, with a focus on upcoming PDUFA catalyst on December 7th. Some traders are focused on technical bounce plays given the cash position, while others express concerns over executive performance and credibility.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending amid discussions about its potential as a leading Layer-2 solution, with community members noting its strong performance, recent breakout, and growing BTCFi integration. Key talking points include the increasing amount of staked $STRK and $BTC on the network, along with optimism surrounding advancements in scaling and privacy. Some community members are drawing comparisons to $ZEC and highlighting the project's focus on bringing privacy to Layer-2.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to news of partnerships and potential growth in the rare earth sector, particularly after an analyst upgrade. Community members are discussing the company's strategic importance in securing the U.S. rare earth supply chain amid concerns about China's dominance. Bullish sentiment is fueled by potential government support and long-term contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Matthew Kaplan Acquires 11,000 Shares of Nuvectis Pharma (NASDAQ:NVCT) Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) Director Matthew Kaplan purchased 11,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 5th. The stock was...

Nuvectis Pharma (NASDAQ:NVCT) CEO Buys $28,600.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur purchased 5,000 shares of the company's stock in a transaction that occurred on Wednesday, November 5th. The stock was acquired...

Nuvectis Pharma (NASDAQ:NVCT) Director Buys $75,270.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) Director Juan Sanchez purchased 13,000 shares of the firm's stock in a transaction on Wednesday, November 5th. The shares were acquired at an...

Nuvectis Pharma FY2029 EPS Forecast Lifted by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Analysts at Roth Capital increased their FY2029 earnings estimates for shares of Nuvectis Pharma in a note issued to investors on Tuesday, November...

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.
read more...

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors...

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Summit Therapeutics Breakthrough with Ivonescimab The recent breakthrough with Summit Therapeutics Ivonescimab (SMT112) reverberated not just in the medical industry but also across the markets. In...

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...

FY2028 Earnings Estimate for Nuvectis Pharma, Inc. Issued By Roth Capital (NASDAQ:NVCT)

Nuvectis Pharma, Inc. (NASDAQ:NVCT  Free Report)  Stock analysts at Roth Capital upped their FY2028 earnings estimates for Nuvectis Pharma in a research note issued on Thursday...

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating...

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.31	--	--	N/A
Q3 '25	-$0.25	-$0.44	-76.00%	MISSED
Q2 '25	-$0.25	-$0.30	-19.21%	MISSED
Q1 '25	-$0.25	-$0.27	-6.30%	MISSED
Q4 '24	-$0.25	--	--	N/A

NVCT
Nuvectis Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest NVCT News

NVCTNuvectis Pharma Inc